Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy

2013 ◽  
Vol 56 (3) ◽  
pp. 272-273
Author(s):  
D. Karpman ◽  
R. Tati ◽  
A.-C. Kristoffersson ◽  
A.-L. Ståhl ◽  
J. Rebetz ◽  
...  
Blood ◽  
2019 ◽  
Vol 134 (13) ◽  
pp. 1095-1105 ◽  
Author(s):  
Liang Zheng ◽  
Di Zhang ◽  
Wenjing Cao ◽  
Wen-Chao Song ◽  
X. Long Zheng

Abstract This study in mice suggests a synergistic role of ADAMTS13 deficiency and complement “hyperactivatability” in the pathogenesis of thrombotic microangiopathy.


2013 ◽  
Vol 191 (5) ◽  
pp. 2184-2193 ◽  
Author(s):  
Ramesh Tati ◽  
Ann-Charlotte Kristoffersson ◽  
Anne-lie Ståhl ◽  
Johan Rebetz ◽  
Li Wang ◽  
...  

Blood ◽  
2015 ◽  
Vol 126 (18) ◽  
pp. 2085-2090 ◽  
Author(s):  
Edward M. Conway

Abstract Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. Excess complement activation underlies atypical HUS and is evident in Shiga toxin–induced HUS (STEC-HUS). This Spotlight focuses on new knowledge of the role of Escherichia coli–derived toxins and polyphosphate in modulating complement and coagulation, and how they affect disease progression and response to treatment. Such new insights may impact on current and future choices of therapies for STEC-HUS.


Immunobiology ◽  
2017 ◽  
Vol 222 (2) ◽  
pp. 119-127 ◽  
Author(s):  
Péter Farkas ◽  
Dorottya Csuka ◽  
Bálint Mikes ◽  
György Sinkovits ◽  
Marienn Réti ◽  
...  

2017 ◽  
Vol 23 (3) ◽  
pp. S244-S245 ◽  
Author(s):  
Seth Joshua Rotz ◽  
Nathan Luebbering ◽  
Bradley P. Dixon ◽  
Christopher E. Dandoy ◽  
Eleni Gavriilaki ◽  
...  

Blood ◽  
2017 ◽  
Vol 130 (10) ◽  
pp. 1259-1266 ◽  
Author(s):  
Nicholas J. Gloude ◽  
Pooja Khandelwal ◽  
Nathan Luebbering ◽  
Dana T. Lounder ◽  
Sonata Jodele ◽  
...  

Key Points dsDNA production peaks 14 days after HSCT, likely a result of IL-8–driven neutrophil recovery. dsDNA production may serve as a mechanistic link between endothelial injury, TA-TMA, and GVHD.


2019 ◽  
Vol 119 (09) ◽  
pp. 1433-1440 ◽  
Author(s):  
Eleni Gavriilaki ◽  
Akrivi Chrysanthopoulou ◽  
Ioanna Sakellari ◽  
Ioannis Batsis ◽  
Despina Mallouri ◽  
...  

AbstractTransplant-associated thrombotic microangiopathy (TA-TMA) is a severe and life-threatening complication of hematopoietic cell transplantation (HCT) that often coincides with graft-versus-host-disease (GVHD). Although endothelial damage seems to be the common denominator for both disorders, the role of complement system, neutrophils, and coagulation has not been clarified. In an effort to distinguish the pathogenesis of TA-TMA from GVHD, we evaluated markers of complement activation, neutrophil extracellular trap (NET) release, endothelial damage, and activation of coagulation cascade in the circulation of patients with these two disorders, as well as control HCT recipients without TA-TMA or GVHD. We observed that the terminal complement product C5b-9 levels, the levels of markers of NET formation, and thrombin–antithrombin complex levels were significantly increased in the TA-TMA group compared with patients without complications, whereas there was no significant difference between the GVHD and the control group. On the other hand, the levels of circulating thrombomodulin, an endothelial damage marker, were significantly increased in both TA-TMA and GVHD patients. These findings propose a role for the interplay between complement system, neutrophil activation through NET release, and activation of the coagulation cascade in TA-TMA.


Sign in / Sign up

Export Citation Format

Share Document